Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04877093 · ClinicalTrials.gov registry record · Phase 3
Repurposing Low-Dose Clonidine for PTSD in Veterans
A Phase 3 study of Post Traumatic Stress Disorder and PTSD, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT04877093: Recruiting Phase 3 study of Post Traumatic Stress Disorder and PTSD, sponsored by Wake Forest University Health Sciences.
NCT04877093 is a Phase 3 study of Post Traumatic Stress Disorder and PTSD that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 32 participants, below the 664-participant average among 262 other Post Traumatic Stress Disorder trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04877093, a Phase 3 study of Post Traumatic Stress Disorder and PTSD, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
Hypothesis: Veterans with PTSD prescribed clonidine will demonstrate improvements in PTSD symptoms, including daytime, nighttime, and sleep-related behaviors.
Primary Outcome
Scored 0-21, where higher scores indicate worse sleep quality.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Clonidine Pill
Study Locations (1)
Wisconsin
- Aurora Psychiatric Hospital - Wauwatosa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2023-06-01 |
| Est. Completion | 2026-03-31 |
| Phase | Phase 3 |
What NCT04877093 shows while recruiting
NCT04877093 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 664-participant average among 262 other Post Traumatic Stress Disorder trials with a reported enrollment target (95% lower).
The record links to 3 conditions, with Post Traumatic Stress Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04877093 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT04877093 about?
NCT04877093 is a clinical study titled "Repurposing Low-Dose Clonidine for PTSD in Veterans". Hypothesis: Veterans with PTSD prescribed clonidine will demonstrate improvements in PTSD symptoms, including daytime, nighttime, and sleep-related behaviors.
What is the current status of trial NCT04877093?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 32 participants. The study started on 2023-06-01. Estimated completion is 2026-03-31.
What conditions does trial NCT04877093 study?
This clinical trial studies the following conditions: Post Traumatic Stress Disorder, PTSD, Sleep.
What interventions are being tested in trial NCT04877093?
The interventions under investigation include: Placebo (OTHER), Clonidine Pill (DRUG).
Who is sponsoring clinical trial NCT04877093?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04877093 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Post Traumatic Stress Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04877093's enrollment target sits among peer trials
32 206th of 262 higher than 56 of 262 other Post Traumatic Stress Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Post Traumatic Stress Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD (EMPOWER-1)
RECRUITING · Phase 3
-
Goal-Directed Sedation in Mechanically Ventilated Infants and Children
RECRUITING · Phase 3
-
MDMA-assisted Massed Prolonged Exposure for PTSD
RECRUITING · Phase 3
-
Predicting Responses to PTSD Treatment With Iris and Cardiovascular Tests
ACTIVE NOT RECRUITING · Phase 3
-
Frontline Clinician Psilocybin Study
COMPLETED · Phase 3
-
Maximizing Treatment Outcome and Examining Sleep in Post-traumatic Stress Disorder (PTSD)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI